IL-4Rα Inhibitor for Atopic Disease

Howard Y Chang; Kari C Nadeau

doi:10.1016/j.cell.2017.06.046

IL-4Rα Inhibitor for Atopic Disease

Cell. 2017 Jul 13;170(2):222. doi: 10.1016/j.cell.2017.06.046.

Authors

Howard Y Chang¹, Kari C Nadeau²

Affiliations

¹ Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: howchang@stanford.edu.
² Stanford University School of Medicine, Stanford University, Stanford, CA, USA. Electronic address: knadeau@stanford.edu.

PMID: 28708993
DOI: 10.1016/j.cell.2017.06.046

Abstract

Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF.

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Clinical Trials as Topic
Dermatitis, Atopic / drug therapy*
Drug Approval
Humans
Interleukin-4 Receptor alpha Subunit / antagonists & inhibitors
Molecular Targeted Therapy

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
IL4R protein, human
Interleukin-4 Receptor alpha Subunit
dupilumab